Editorial: Focal glomerular sclerosis.
D002699:Chlorambucil / Q000627:therapeutic use; D003168:Complement Fixation Tests; D003165:Complement System Proteins / Q000032:analysis; D004804:Eosinophils; D005260:Female; D005337:Fibrin / Q000378:metabolism; D006801:Humans; D006818:Hyalin / Q000378:metabolism; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007223:Infant; D007231:Infant, Newborn; D007678:Kidney Glomerulus / Q000276:immunology / Q000473:pathology*; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications* / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D006435:Renal Dialysis; D012598:Sclerosis / Q000150:complications / Q000473:pathology
D007074:Immunoglobulin G; D007075:Immunoglobulin M; D002699:Chlorambucil; D005337:Fibrin; D003165:Complement System Proteins; D011241:Prednisone